new treatments development are supported by funding source other than industry.

Abstract AB0614 – Table 1

<table>
<thead>
<tr>
<th>Phase</th>
<th>Worldwide (n)</th>
<th>EU (n)</th>
<th>Spain (n)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Early Phase 1</td>
<td>7 1 2 1.2 0 0.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phase 1</td>
<td>76 12.4 17 10.2 3 5.5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phase 1/2</td>
<td>24 3.9 4 2.4 0 0.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phase 2</td>
<td>143 23.4 57 34.3 23 41.8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phase 2/3</td>
<td>15 2.5 5 3.0 1 1.8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phase 3</td>
<td>76 12.4 34 20.5 21 38.2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phase 4</td>
<td>47 7.7 7 4.2 3 5.5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No data</td>
<td>223 36.5 40 24.1 4 7.3</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* The percentages have been rounding

Conclusions: Europe participate in more than a quarter of Lupus clinical studies and Spain is the third European country participating in those clinical studies. New treatment development studies are the main CT performed worldwide and the percentage is even higher in Spain. Regarding the study phase, the distribution of CT in Europe and Spain are similar although phase I studies in Spain are less frequent. From all studies registered, the majority are non-industry sponsored studies. In Europe and in Spain the situation is the opposite, as 87.3% of the studies are pharma-sponsored studies.


AB0615

CHANGES IN SOMATOSENSEW EVOKED POTENTIALS IN PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME

E. Dziadkowski,1 A. Sebastian,2 M. Wieczorek,2 E. Kusińska,3 M. Waliszewska-Prościol,4 P. Wiaż,2 M. Ejma,1 Department of Neurology;4 Department of Rheumatology and Internal Medicine, Wrocław Medical University, 3Department of Geoinformatics and Cartography, Institute of Geography and Regional Development, Wrocław, Poland

Background: Primary Sjogren’s syndrome (pSS) is a chronic autoimmune disease, which, in addition to impaired function of exocrine glands, can affect other organs including nervous system.

Objectives: The aim of the study was to establish whether in patients with pSS without central nervous system (CNS) involvement, the function of the central portion of the sensory pathway can be challenged.

Methods: In 33 patients diagnosed with pSS without clinical features of CNS damage and normal head CT scan, somatosensory evoked potentials (SEP) were studied. The results were compared to other clinical parameters of the disease, particularly to immunological status. The control group consisted of 20 healthy volunteers selected with respect to age and sex.

Results: Mean latency of all components of SEP were considerably prolonged in patients compared to the control group. Mean interpeak latency N20-N13 (duration of central conduction TT) did not differ significantly between the groups. However, in the study group, mean amplitude of N20P22 and N13P16 was significantly higher compared to healthy individuals. In patients with pSS, significant differences in SEP parameters depending on duration of the disease, duration of arthralgia and presence of SSA and SSB antibodies were noted. No significant differences in mean SEP parameters were observed with respect to skin lesions, xerophthalmia, current joint pain and swelling, focus score, levels of C3 and C4 complement components, ESR, CRP and presence of Ro52 antibodies.

Conclusions: The authors confirmed central nervous system involvement observed in patients with pSS. They also showed dysfunction of the central sensory neuron as a difference in amplitude of cortical response, which indicates subclinical damage to the CNS.


AB0616

THE CORRELATION BETWEEN FOCUS SCORE AND ULTRASONOGRAPHY OF MAJOR SALIVARY GLANDS IN PRIMARY SJÖGREN SYNDROME

A. Sebastian,1 J. Stokić,2 A. Haler,1 P. Wiaż.1,2 Department of Rheumatology and Internal Medicine;2 Department of General and Paediatric Radiology, 1Division of Pathomorphology and Clinical Cytology, Department of Pathomorphology, Wrocław Medical University, Wrocław, Poland

Background: Currently, the role of salivary gland ultrasonography (SGUS) in the diagnosis of primary Sjögren’s syndrome (pSS) is being determined. So far, in none of the proposed classification criteria for pSS SGUS is taken into consideration. The most recent analyses of patients show that SGUS can prove to be useful in the identification of even early forms of pSS.

Objectives: We analyzed the SGUS changes in patients with pSS and its correlations with focus score (FS) of minor salivary glands and immunological and laboratory profile.

Methods: We included 68 patients with pSS in the mean age of 51, based on the classification criteria from 2002.

Results: In 33 (48%) patients were abnormal findings in major salivary glands detected (table 1). Scattered hypoechogenic changes of different size were the most common observed changes in SGUS, mainly in parotid glands.

Abstract AB0616 – Table 1. Abnormal images in salivary and mandibular glands in patients with pSS.

<table>
<thead>
<tr>
<th>Number of patients – 33</th>
<th>Parotid and submandibular glands</th>
</tr>
</thead>
<tbody>
<tr>
<td>Changes in SGUS</td>
<td>Parotid glands 23 patients (70% of changes)</td>
</tr>
<tr>
<td></td>
<td>Submandibular glands 10 patients (30% of changes)</td>
</tr>
<tr>
<td>SGUS changes</td>
<td>gland enlargement 48% of changes</td>
</tr>
<tr>
<td></td>
<td>scattered hypoechogenic changes of different size 85% of changes</td>
</tr>
<tr>
<td></td>
<td>fibrosis 6% of changes</td>
</tr>
<tr>
<td></td>
<td>lymph glands 15% of changes</td>
</tr>
<tr>
<td></td>
<td>gland atrophy 12% of changes</td>
</tr>
<tr>
<td></td>
<td>ducts enlargement 3% of changes</td>
</tr>
</tbody>
</table>

The FS was significantly higher in patients with changes in SGUS compared to the patients with normal images of major salivary glands (2.6 SD 1.3 vs 1.8 SD 1.2; p=0.02).

In patients with SGUS abnormalities the hypergamma Globulinemia was most often observed (1.7 g/dl vs 1.2 g/dl; p=0.02). There was not the correlation between changes in major salivary glands and age (p=0.5), CRP value (p=0.1), ESR value (p=0.1), with blood cell count (p=0.1), rheumatoid factor (p=0.1), dry eye (p=0.1), oral dryness (p=0.2), anti-SSA antibodies (p=0.5), anti-SSB antibodies (p=0.2), anti-Ro52 antibodies (p=0.4) observed.

Conclusions: SGUS is a useful tool in patients with pSS. The abnormal images in SGUS of major salivary glands correlated with focus score of minor salivary glands and hypergamma Globulinemia but not with specific antibodies.


AB0617

ACROSS-SECTIONAL STUDY OF NAILFOLD MICROVASCULAR CHANGES IN INDIAN PATIENTS WITH RNP+ LUPUS AND MCTD USING NAILFOLD VIDEOCAPILLAROSCOPY

P.P. Chebbi,1 R. goel,2 R. aihal,1 G. mahasampath,2 D. danda.1 1Clinical Immunology and Rheumatology, 2Biostatistics, Christian Medical college, Vellore, India

Background: Nailfold capillary (NFC) changes represent degree of microvascular involvement in autoimmune connective tissue diseases. Anti U1-RNP is associated with specific internal organ involvement in SLE. Nailfold capillaroscopy may objectively predict the systemic microvascular abnormalities in SLE patients with positive Anti U1-RNP antibody.

Objectives: To study nailfold microvascular changes (NFVC) in SLE patients with RNP+ and compare them with NFVC changes observed in patients with RNP negative SLE and Mixed connective tissue disease (MCTD).

Methods: Nailfold videocapillaroscopic (NFVC) examination (OptiMediscopes, 200X) was performed in consecutive patients satisfying classification criteria of


PREVALENCE OF HYPOVITAMINOSIS D IN ADULTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS AND THE RELATIONSHIP WITH SLEDAI 2K IN PATIENTS TREATED IN TWO RHEUMATOLOGY SERVICES, BOGOTA 2017

R.A. Guzman Moreno, L.G. Piñeros, J. Garcia, L.M. Pombo, A. Teheran, J. Bustillo, K.A. Guzman Moreno, V. Cadavid, M.C. Mejia. Inmuno Reumatologia and Internal Medicine, IDEARG, Fundación Universitaria Juan N Corpas, Bogota, Colombia

Background: Vitamin D is a steroid hormone with pleiotropic effects on physiological processes. Among others, immune system regulation and their analogues prevent symptom development of autoimmune diseases such as SLE. A previous research in a colombian clinic found a prevalence of hypovitaminosis D of 87% in healthy population, but hypovitaminosis D is higher in SLE patients than healthy controls.

Objectives: To establish the prevalence of hypovitaminosis D in patients with SLE and relationship with SLEDAI – 2K.

Methods: A cross sectional study was carried out. 80 medical records with a diagnosis of SLE or CIE-10 M00-M36 were identified and we included patients± 18 years of age who meet at least 4 of the 11 criteria to diagnoses of SLE for medical record. The analysis included means, DS and Kruskall Wallis with p-value<0.05.

Results: The majority of patients are women (94%), with an average age of 46.31 years (mean: 46.31 years) were assessed by DXA (all of Caucasian ethnicity, mean disease duration: 15.49 years; 61% denied any physical activity). SLE medication included glucocorticoids (93.9%), and osteoporosis has become highly important. In this disease, osteoporotic risk factors such as female gender, early onset of disease leading to long disease duration, high degree of systemic inflammation, high frequencies of glucocorticoid usage often at higher doses, and chronic fatigue or pain compromising physical activities are often present in combination.

Conclusions: Presen of anti-U1 RNP antibody is associated with micro-vascular abnormalities in SLE as detected by NFVC. Patients with MCTD have more profound abnormalities as compared to RNP+SLE patients.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.7013

AB0619

MANY PERIPHERAL FRACTURES DESPITE NORMAL BONE MINERAL DENSITY CAUCASIAN SLE PATIENTS


Background: Clinical outcome has improved in systemic lupus erythematosus (SLE) and thus, early management of comorbidities like cardiovascular disease and osteoporosis has become highly important. In this disease, osteoporotic risk factors such as female gender, early onset of disease leading to long disease duration, high degree of systemic inflammation, high frequencies of glucocorticoid usage often at higher doses, and chronic fatigue or pain compromising physical activities are often present in combination. Rh-GIOP (NCT02719314) is an ongoing prospective study monitoring glucocorticoid (GC)-induced osteoporosis of rheumatic patients, established in 2015 at the Charité University Hospital. To date, the database comprises clinical data and bone mineral density data measured by dual x-ray absorptiometry (DXA) of 592 patients with inflammatory rheumatic diseases.

Objectives: To quantify bone mineral density and fractures in SLE patients. Methods: Bone mineral density (BMD) data of SLE patients as measured by dual x-ray absorptiometry (DXA) were analysed with regard to their relation to detailed clinical data.

Results: 43 female and 6 male SLE patients aged between 20 and 77 years (mean: 46.31 years) were assessed by DXA (all of Caucasian ethnicity, mean disease duration: 15.49 years; 61% denied any physical activity). SLE medication included glucocorticoids (93.9%; mean cumulative dose: 25.5 g), antimalarials (67.3%), azathioprine (30.6%), mycophenolate-mofetil acid (22.4%), belimumab (16.3%), cyclophosphamide (10.2%) and methotrexate (8.1%). In 26 (60.5%) of all studied SLE patients, 36 (92.3%) peripheral and 3 (7.7%) vertebral fractures were recorded. Notably, 6 of these patients with vertebra fractures were younger than 30 and only 4 older than 60 years. 10 of all 39 fractures (25.6%) were low-trauma fractures. Of note, 11/26 patients (42.3%) with fractures had a normal BMD, 9/26 (34.6%) osteopenia and 6/26 (23.7%) osteoporosis, while only 4 (15.4%) of them initially received anti-osteoporotic medication.

Conclusions: There is a high occurrence of peripheral fractures in SLE. Moreover, 4 out of 10 SLE patients developed fractures despite a normal BMD, stressing that this parameter is of limited value for correctly identifying the fracture risk in SLE. The analysis of a larger number of patients and in-depth analyses are necessary to improve management of osteoporosis and to better prevent fractures in SLE patients.

REFERENCE:

Disclosure of Interest: R. Biesen Grant/research support from: Amgen, BMS, Celgene, Generic Assays GSK, Horizon, medac, Mundipharma, Pfizer and Roche, E. Wiebe Grant/research support from: Amgen, BMS, Celgene, Generic Assays GSK, Horizon, medac, Mundipharma, Pfizer and Roche, D. Freier Grant/research support from: Amgen, BMS, Celgene, Generic Assays GSK, Horizon, medac, Mundipharma, Pfizer and Roche, K. Zeiner Grant/research support from: Amgen, BMS, Celgene, Generic Assays GSK, Horizon, medac, Mundipharma, Pfizer and Roche, U. Schneider: None declared, T. Alexander: None declared, F. Hiene: None declared, F. Buttgereit Grant/research support from: Amgen, BMS, Celgene, Generic Assays GSK, Horizon, medac, Mundipharma, Pfizer and Roche


Abstract AB0618 – Figure 1

Conclusions: Patients with active systemic lupus erythematosus (SLE) have hypovitaminosis D more frequently and we noticed that patients with renal involve-ment have the lowest levels of vitamin D, which justifies a later analysis.